Otros idiomas NLS Pharmaceutics AG

Acciones

NLSP

CH0523961370

Mercado cerrado - Nasdaq Otros sitios de cotización 22:00:00 27/06/2024			Varia. Cinco días.	Varia. 1 de enero.
0,24 ^USD	+31,43 %		+28,41 %	-59,32 %

27/06	Actualización del sector: Los valores del sector sanitario caen a última hora de la tarde	MT
27/06	Actualización del sector: Atención sanitaria	MT

Otros idiomas

Desbloquee todas las noticias: ¡Sea el primero en enterarse y reaccione antes que los mercados!

Inscripción 100% Gratuita

Sector Update: Health Care Stocks Slipping Late Afternoon	27/06
Sector Update: Health Care	27/06
Top Midday Gainers	27/06
European Equities Close Mostly Lower Thursday; Bank of England Warns of 'Sharp Correction' Risk	27/06
NLS Pharmaceutics Reports Preclinical Data for Potential Parkinson's Disease Treatments; Shares Jump	27/06
Wall Street Set to Open Marginally Lower Thursday as Investors Parse Bullish Economic Data	27/06
Nasdaq Panel Grants NLS Pharmaceutics Request for Extension to Comply with Continued Listing Requirements	26/06
NLS Pharmaceutics : Invitation to the Ordinary Shareholders’ Meeting of NLS Pharmaceutics Ltd., Zurich, Switzerland Form 6 K	25/06
NLS Pharmaceutics AG Publication of New Patent Application for Next-Gen Dual Non-Sulfonamide Orexin Receptor Agonists	11/06
NLS Pharmaceutics Says New Patent Application for Dual Non-Sulfonamide Orexin Receptor Agonists Published by WIPO	11/06
NLS Pharmaceutics Reports Positive Results from Study KO-874 on Mazindol's Neuroprotective Effects in Narcoleptic-like Rat Model	29/05
NLS Pharmaceutics : ASCP Annual Meeting, Miami, May 28-May 31, 2024	28/05
NLS Pharmaceutics : ADDENDUM TO THE - Form 6-K	22/05
NLS Pharmaceutics Ltd. Enters into Additional Bridge Loan Addendums, or the Second Bridge Loan Addendums	22/05
NLS Pharmaceutics AG Reports Earnings Results for the Full Year Ended December 31, 2023	15/05
NLS Pharmaceutics : SECOND ADDENDUM TO THE - Form 6-K	14/05
Nls Pharmaceutics Ltd. Announces Resignation of Anthony S. Walsh as A Member of the Board of Directors	08/04
NLS Pharmaceutics Ltd. announced that it has received $1.75 million in funding	03/04
NLS Pharmaceutics : Various Claims Against the Company - Form 6-K	20/03
NLS Pharmaceutics : SECOND ADDENDUM TO THE - Form 6-K	20/03

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas NLS Pharmaceutics AG

Acciones

NLSP

CH0523961370

Otros idiomas

Filtros